ArticleBMC cancer2026
Recurrence-free survival is prolonged in high-grade serous ovarian cancer with high PD-L1 expression.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-grade serous ovarian carcinoma (HGSOC) is the most common and clinically aggressive epithelial ovarian cancer subtype and is frequently characterized by relapse despite standard treatment. The FIGO staging system guides treatment decisions and provides prognostic information, but patients within the same stage may display markedly different treatment responses and survival outcomes. Increasing evidence indicates that the tumor microenvironment contributes to recurrence and therapeutic responsiveness. This study focused on the PD-1/PD-L1 immune-checkpoint pathway and evaluated PD-1/PD-L1-positive immune-cell density as a potential prognostic biomarker in HGSOC.
methodsThis retrospective study included 47 patients with HGSOC and matched recurrent tumor samples. Immunohistochemistry was performed on tissue microarrays constructed from paired primary and recurrent formalin-fixed paraffin-embedded samples. PD-1 and PD-L1 immune-cell densities were quantified on evaluable TMA cores, dichotomized into low- and high-density groups, and correlated with recurrence-free survival (RFS), overall survival (OS), chemosensitivity, and clinicopathological parameters. Kaplan-Meier and Cox regression analyses were used to evaluate survival associations.
resultsPatients with high primary PD-L1 immune-cell density had longer RFS than those with low PD-L1 density (log-rank p = 0.032). In contrast, no significant difference in RFS was observed between patients with high versus low PD-1 immune-cell density (p = 0.18). Neither PD-L1 nor PD-1 density showed a statistically significant association with OS in this cohort.
conclusionIn this retrospective TMA-based HGSOC cohort, high PD-L1 immune-cell density in the primary tumor was associated with prolonged RFS. These findings should be considered hypothesis-generating and warrant validation in larger, prospectively collected HGSOC cohorts before clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.